Apogee Therapeutics Inc 2025年季度报告

Large accelerated filer☐Non-accelerated filer☐☐share. Table of ContentsPART IFINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial Statements (Unaudited)Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024Condensed Consolidated Statement of Operations for the Three Months Ended March 31, 2025 and2024Condensed Consolidated Statement of Comprehensive Loss for the Three Months Ended March 31,2025 and 2024Condensed Consolidated Statement of Stockholders’ Equity for the Three Months Ended March 31,2025 and 2024Condensed Consolidated Statement of Cash Flows for the Three Months Ended March 31, 2025 and2024Notes to the Unaudited Interim Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPARTIIOTHER INFORMATIONItem 1.Legal ProceedingsItem1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignaturesTable of Contents APOGEE THERAPEUTICS, INC.TABLE OF CONTENTS Page This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains “forward-looking statements” within themeaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and arebased on current expectations, estimates, forecasts and assumptions. All statements other than statements ofhistorical fact included in this Quarterly Report, including statements concerning our plans, objectives, goals,strategies, future events, future revenues or performance, capital requirements or financing needs, capitalexpenditures, commitments, preclinical studies, clinical trials, plans or intentions relating to product candidates,expected markets, business trends and other statements, including without limitation, those discussed under thesections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results ofOperations”, are forward-looking statements. In some cases, you can identify forward-looking statements byterms such as “may,” “might,” “will,” “would,” “shall,” “objective,” “intend,” “target,” “should,” “could,” “can,”“expect,” “anticipate,” “believe,” “design,” “estimate,” “forecast,” “predict,” “potential,” “plan,” “seek,” or“continue”or the negative of these terms and similar expressions intended to identify forward-lookingstatements. Forward-looking statements reflect our current views with respect to future events. Given thesignificant risks and uncertainties, you should not place undue reliance on these forward-looking statements.There are a number of risks, uncertainties and other factors that could cause our actual results to differ materiallyfrom the forward-looking statements expressed or implied in this Quarterly Report. Such risks, uncertainties andother factors include, among others, the following:•our plans to develop and commercialize our programs for the treatment of atopic dermatitis, asthma, eosinophilicesophagitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications withhigh unmet need;•our ability to obtain funding for our operations, including funding necessary to complete the development andcommercialization of our programs;•the timing and focus of our ongoing and future preclinical studies and clinical trials and the reporting of datafrom those studies and trials;•the beneficial characteristics, safety, efficacy and therapeutic effects of our programs;•our plans relating to the further development of our programs, including additional indications we may pursue;•the size of the market opportunity for our programs, including our estimates of the number of patients who sufferfrom the diseases we are targeting;•our continued reliance on third parties to conduct additional preclinical studies and clinical trials of ourprograms and for the manufacture of our product candidates for preclinical studies and clinical trials;•the success, cost and timing of our preclinical and clinical development activities and planned clinical trials;•our plans regarding, and our ability to obtain, and negotiate favorable terms of, any collaboration, licensing orother arrangements that may be necessary or desirable to develop, manufacture or commercialize our programs;•the timing of and our ability to obtain and maintain regulatory approvals for our programs, as well as potentialfuture programs;•the rate and degree of market acceptance and clinical utility of our programs;•the success of competing treatments that are or may become available;•our ability to attract and retain key management and technical personnel;•our expectations regarding our ability to obtain, maintain and enforce intellectual property protection for ourprograms;•our financial performance;•the period over which we estimate our exis